Virtual or “siteless” clinical trials allow trial coordinators and patients to conduct clinical study visits via online video calls, and collect data via handheld or wearable devices. In addition, virtual trials increase the size and diversity of the patient pool, accelerate recruiting, and generate more informative, clinically-relevant data that is accepted by regulatory agencies.
However, moving from traditional to virtual trials presents challenges as clinical trial sponsors learn how to design, execute, and complete effective virtual trials. To assure success, trial sponsors need to better understand the digital tools and platforms used in virtual trials, how to manage the data collection they enable, and the pitfalls to avoid.
In this webinar, Bernard Munos, a pioneering pharmaceutical industry innovator, and Transparency Life Sciences co-founder Dr. Tomasz Sablinski, will provide an overview of the strategies leaders are finding helpful in adopting and adapting to virtual trials.
They will demystify the process of conducting virtual trials, examine the current state of virtual studies, discuss tools available for conducting virtual trials, and explore how to maximize benefits while reducing the risks of this exciting new approach.
This webinar will help you understand how digital innovation can help improve the productivity of your clinical trials and give you the background you need to decide which trials are virtual-ready and which may be amenable to a hybrid approach. It will also help you develop an overall strategy for designing and executing a virtual trial.
Bernard Munos, Founder, InnoThink
Bernard Munos studies pharmaceutical innovation, what causes it and how to get more of it. He is founder and chief apostle of InnoThink, a consultancy dedicated to bringing evidence-based innovation models to the pharmaceutical industry. Previously an advisor for corporate strategy at Eli Lilly, he has long focused on disruptive innovation in drug development and on the radical redesign of R&D. Munos’ research has been published in Nature and Science, and he has presented his findings to the National Academies, the Institute of Medicine, the President’s Cancer Panel, the National Institutes of Health Leadership Forum, the World Health Organization, the OECD, the Kauffman Foundation, the U.S. Patent and Trademark Office, the Council for American Medical Innovation, and many others. He received his MBA from Stanford University, and holds other graduate degrees from the University of California, Davis and the Paris Institute of Technology for Life, Food and Environmental Sciences.
Tomasz Sablinski, MD, PhD, CEO, Transparency Life Sciences
Tomasz Sablinski, MD, PhD has been named a “Champion of Change” for the past three years by the publication Medicine Maker. Dr. Sablinski has more than three decades of experience in medicine and healthcare, including 15 years of managing drug development at Novartis, overseeing a drug development portfolio at Auven Therapeutics and teaching at Harvard Medical School. A virtual trials pioneer, he co-founded Transparency Life Sciences in 2012 and serves as Chief Executive Officer with the goal of using digital technologies to accelerate drug development with improved data and reduced costs.
Who Should Attend?
Biopharmaceutical researchers, drug developers and CRO professionals who want to learn how to accelerate the development and commercialization of therapeutics using virtual, siteless, or hybrid clinical trials and the latest digital technologies. This webinar will especially appeal to those working in:
- Drug development
- Clinical trial design
- Patient engagement
- Digital health
- New product strategy and planning
What You Will Learn
- What strategies industry leaders are using to integrate virtual and traditional trials
- How to decide whether virtual, siteless, hybrid or conventional trials are the best option for your investigational product
- How digital tools enable the conduct of virtual trials and collect regulatory friendly data
- Strategies for overcoming internal challenges, and maximizing the benefits of conducting remote trials with mobile digital health apps
Transparency Life Sciences (TLS)
Transparency Life Sciences (TLS) is the first all-digital clinical development services company. Rapid advances in digital technology and strong regulatory support create a historic opportunity for TLS to catalyze a fundamental transformation in clinical trial design and execution, significantly improving the quality of clinical trials while reducing their overall cost. TLS’s approach combines crowdsourcing and mobile health technology to advance drug candidates through clinical trials with unprecedented efficiency and patient, prescriber, and regulatory relevance. The use of digital technology allows TLS to reduce or eliminate reliance on physical study sites that are expensive, complex and inconvenient for patients, and limit the geographic scope of enrollment. For more information, visit